![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Processa Pharmaceuticals Inc | NASDAQ:PCSA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.09 | -5.00% | 1.71 | 1.70 | 1.79 | 1.85 | 1.73 | 1.85 | 14,117 | 00:11:18 |
Conference Call Information
To participate in this event, please dial in approximately 5 to 10 minutes before the beginning of the call.
Date: May 13, 2021Time: 5:30 p.m. ETToll Free: 888-506-0062; Entry Code: 396394International: 973-528-0016; Entry Code: 396394
Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/41274
Conference Call Replay Information
Toll-free: 877-481-4010International: 919-882-2331Replay Passcode: 41274
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal cancer and breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (GI motility/gastroparesis). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.ProcessaPharma.com .
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the registration statement relating to the securities being sold in this offering, which identifies important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:Michael Floydmfloyd@processapharma.com301-651-4256
James CarbonaraHayden IR(646) 755-7412james@haydenir.com
1 Year Processa Pharmaceuticals Chart |
1 Month Processa Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions